Argo Biopharma announced that its first self-developed siRNA new drug has received HREC approval, and it will shortly begin Phase 1 clinical study in Australia.

siRNA (small interfering RNA) drugs are a new class of pharmaceuticals that have emerged in recent years. They have the advantages of multiple druggable targets, strong efficacy, good safety, and low frequency of administration. Additionally, they have a broad variety of indications, covering cardiovascular diseases, rare diseases, neurological diseases, viral hepatitis, ophthalmic diseases, tumors, etc. As a result, they have emerged as one of the world's cutting-edge medical fields with enormous development potential.

Argo Biopharma was established in 2021 by several scientists with rich experience in the development of RNAi drugs. It is dedicated to developing a new generation of siRNA drugs to provide better treatments for patients around the world.

Argo Biopharma announced in May 2021 that it had closed an angel round of financing nearly US $5 million, with Apricot Capital exclusively leading the investment. In March 2022, Argo Biopharma once again announced the completion of series A financing of US $63 million. This round of financing was led by Loyal Valley Capital, and co-invested by CPE fund, TAO CAPITAL, Trinity Fund, and GSR United Capital.

Several preclinical R&D pipelines are being actively promoted by Argo Biopharma, and a number of these pipelines have already reached the IND-enabling stage. It is anticipated that multiple drug candidates will be approved for clinical study by 2023.